Mitralign is a cardiac device company founded by the Accelerated Technologies (ATI) medical device incubator. The company has developed and is currently testing an innovative, catheter-based valve repair technology for first-line percutaneous treatment of functional mitral regurgitation. The novel technology emulates surgical annuloplasty as it delivers a pair of surgical implants directly into the mitral annulus through a catheter.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/16/12 | $35,000,000 | Series D |
Forbion Capital Partners Giza Venture Capital Johnson & Johnson Innovation Medtronic Orchestra Medical Ventures Triathlon Medical Ventures | undisclosed |
| 05/17/16 | $40,000,000 | Series E |
